Apogee Therapeutics to Participate in Upcoming November Investor Conferences

GlobeNewswireNov 4 20:30

BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $100

Futu NewsOct 29 18:31 · Ratings

TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating

Futu NewsOct 28 20:35 · Ratings

Apogee Therapeutics Price Target Maintained With a $87.00/Share by Wedbush

Dow JonesOct 25 23:19 · Ratings

Apogee Therapeutics Analyst Ratings

BenzingaOct 25 23:07 · Ratings

Apogee Therapeutics Unveils Promising Phase 1 Trial Results

TipRanksOct 24 20:28